Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: An antibody-drug conjugate for CD30-positive lymphoid neoplasms
AGED;
ANTIGEN EXPRESSION;
ANTINEOPLASTIC ACTIVITY;
APOPTOSIS;
ARTICLE;
CASE REPORT;
CLASSICAL HODGKIN LYMPHOMA;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG PROTEIN BINDING;
HUMAN;
HUMAN CELL;
HUMAN TISSUE;
INTERNALIZATION;
LARGE CELL LYMPHOMA;
MALE;
SKIN LYMPHOMA;
TREATMENT OUTCOME;
S.H. Swerdlow, E. Campo, N.L. Harris, IARC Press Lyon, France
E. Ralfkiaer, R. Willemze, M. Paulli Primary cutaneous CD30-positive T-cell lymphoproliferative disorders S.H. Swerdlow, E. Campo, N.L. Harris, World Health Organization Classification of Tumours of haematopoietic and lymphoid tissues 2008 IARC Press Lyon, France 300 301
ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International peripheral T-cell lymphoma project
K.J. Savage, N.L. Harris, J.M. Vose ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International peripheral T-cell lymphoma project Blood 111 2008 5496 5504